Mesothelioma and Murine Models of Melanoma and Adenocarcinoma

Another interesting study titled "Effectiveness of CD40 ligand gene therapy in malignant mesothelioma" - American Thoracic Society, New York, NY, Etats-Unis (1989) (Revue) Here is an excerpt. "Summary - Gene delivery of CD40 ligand (CD40L) has shown promise in murine models of melanoma and adenocarcinoma, however, its potential for Thoracic malignancies such as malignant mesothelioma remains unclear in this study, we investigated the hypothesis that CD40L gene therapy would be. Effective on local and distant tumor suppression in mesothelioma using immunocompetent murine model. the use of recombinant adenovirus encoding murine CD40L (AdCD40L), we demonstrated no suppression of in vitro cell growth for the AC29 (mesothelioma) cell lines. However, vaccination of immunocompetent CBA / J mice with AC29 cells treated ex vivo with AdCD40L resulted in significant tumor suppression in vivo compared with controls (P <0.001). AdCD40L Intratumoral inoculation of previously established AC29 tumors gave similar results antitumor and is associated with increased recruitment of intratumoral CD8 + T-lymphocytes. adoptive transfer of CD8 + T-lymphocytes from AdCD40L treated tumor bearing mice conferred protection to naive mice given AC29 tumor challenge. Finally, in mice with two synchronous tumors, treatment of a tumor with AdCD40L resulted in regression of both tumors. These results demonstrate the tumor-specific CD8 + T-AdCD40L cells and support further development AdCD40L for the treatment of malignant mesothelioma ."

Another interesting study entitled "The use of chemotherapy in patients with advanced malignant pleural mesothelioma: a systematic review and practice guidelines" by Ellis, Peter MBBS, PhD, FRACP, Davies, Angela M. MD, FRCPC; Evans, William K. MD, FRCPC, Haynes, Adam E. BSc, Lloyd, Nancy S. BA; lung cancer disease site group of Cancer care Ontario program in evidence-based care
Journal of Thoracic Oncology:. July 2006 - Volume 1 - Issue 6 - pp 591-601 Here is an excerpt: "Abstract - Background: The clinical practice guidelines, based on a systematic review, was developed to determine which chemotherapeutic agents (or combination of substances) showed the highest response rates , improved survival, quality of life or symptom control in patients with advanced malignant pleural mesothelioma.